Sustained Release of Bone Morphogenetic Protein 2 via Coacervate Improves the Osteogenic Potential of Muscle-Derived Stem Cells
From Stem Cells Translational Medicine
The group of Johnny Huard at the University of Pittsburgh, USA have previously isolated and characterized muscle-derived stem cells (MDSCs) (Gharaibeh et al) which have been shown by various groups by be able to undergo osteogenic differentiation given the correct stimuli. They are therefore a potential alternative to bone marrow-derived mesenchymal stem cells for bone tissue engineering. One of these stimuli is continued exposure to BMPs, hindered by the short half-lives in vivo (Jeon et al and Zhao et al) and the requirement of maintaining a localised concentration. The group have also devised a delivery strategy; a poly(ethylene argininylaspartate diglyceride)(PEAD)-heparin complex loaded with BMP2 which forms an emulsion-like aggregation of organic molecules separated from the aqueous phase, or a coacervate (Johnson and Wang), previously used to effectively deliver fibroblast growth factor-2 (FGF2) for therapeutic angiogenesis (Chu et al). Now, in a report in Stem Cells TM, they report on the use of this system with BMP2 to stimulate osteogenesis in MDSCs in vitro and in vivo (Li and Johnson et al).